PMID- 27240347
OWN - NLM
STAT- MEDLINE
DCOM- 20170315
LR  - 20210102
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 17
IP  - 6
DP  - 2016 May 26
TI  - Dendritic-Tumor Fusion Cell-Based Cancer Vaccines.
LID - 10.3390/ijms17060828 [doi]
LID - 828
AB  - Dendritic cells (DCs) are potent antigen-presenting cells (APCs) that play a 
      critical role in the induction of antitumor immunity. Therefore, various 
      strategies have been developed to deliver tumor-associated antigens (TAAs) to DCs 
      as cancer vaccines. The fusion of DCs and whole tumor cells to generate DC-tumor 
      fusion cells (DC-tumor FCs) is an alternative strategy to treat cancer patients. 
      The cell fusion method allows DCs to be exposed to the broad array of TAAs 
      originally expressed by whole tumor cells. DCs then process TAAs endogenously and 
      present them through major histocompatibility complex (MHC) class I and II 
      pathways in the context of costimulatory molecules, resulting in simultaneous 
      activation of both CD4(+) and CD8(+) T cells. DC-tumor FCs require optimized enhanced 
      immunogenicity of both DCs and whole tumor cells. In this context, an effective 
      fusion strategy also needs to produce immunogenic DC-tumor FCs. We discuss the 
      potential ability of DC-tumor FCs and the recent progress in improving clinical 
      outcomes by DC-tumor FC-based cancer vaccines.
FAU - Koido, Shigeo
AU  - Koido S
AD  - Division of Gastroenterology and Hepatology, Department of Internal Medicine, The 
      Jikei University School of Medicine, Kashiwa Hospital, 277-8567 Chiba, Japan. 
      shigeo_koido@jikei.ac.jp.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160526
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Histocompatibility Antigens Class II)
SB  - IM
MH  - Animals
MH  - Antigens, Neoplasm/*metabolism
MH  - CD4-Positive T-Lymphocytes/immunology
MH  - CD8-Positive T-Lymphocytes/immunology
MH  - Cancer Vaccines/*immunology
MH  - Cell Fusion
MH  - Dendritic Cells/*cytology/immunology
MH  - Histocompatibility Antigens Class I/metabolism
MH  - Histocompatibility Antigens Class II/metabolism
MH  - Humans
MH  - Lymphocyte Activation
MH  - Tumor Cells, Cultured/*cytology/immunology
PMC - PMC4926362
OTO - NOTNLM
OT  - cancer vaccines
OT  - cell fusions
OT  - cytotoxic T lymphocyte
OT  - dendritic cell
OT  - whole tumor cell
EDAT- 2016/05/31 06:00
MHDA- 2017/03/16 06:00
PMCR- 2016/06/01
CRDT- 2016/05/31 06:00
PHST- 2016/05/14 00:00 [received]
PHST- 2016/05/19 00:00 [revised]
PHST- 2016/05/23 00:00 [accepted]
PHST- 2016/05/31 06:00 [entrez]
PHST- 2016/05/31 06:00 [pubmed]
PHST- 2017/03/16 06:00 [medline]
PHST- 2016/06/01 00:00 [pmc-release]
AID - ijms17060828 [pii]
AID - ijms-17-00828 [pii]
AID - 10.3390/ijms17060828 [doi]
PST - epublish
SO  - Int J Mol Sci. 2016 May 26;17(6):828. doi: 10.3390/ijms17060828.